Hemab launches SOLARA Phase 3 study for Glanzmann thrombasthenia

Hemab Therapeutics said on November 9 that it had started SOLARA, a Phase 3 evaluation of sutacimig as a preventive treatment for Glanzmann thrombasthenia. The open-label study plans to enroll approximately 75 people between 12 and 70 years old who had at least four treated bleeds in the prior year. Participants will complete a 24-week observation period before receiving 48 weeks of once-weekly sutacimig at 0.2 mg/kg, with annualized treated bleeding serving as the main efficacy measure. The FDA had advised considering randomization, but Hemab selected a single-arm design because of feasibility concerns in this rare disease.

The announcement moves sutacimig into pivotal-stage testing, creating a defined clinical development milestone for Hemab. The FDA's recommendation for a randomized trial makes the chosen single-arm design an important regulatory consideration for investors.

  • 1SOLARA is designed to enroll approximately 75 participants aged 12 to 70 years with Glanzmann thrombasthenia.
  • 2The protocol includes a 24-week run-in followed by 48 weeks of treatment with subcutaneous sutacimig dosed at 0.2 mg/kg once weekly.
  • 3The primary measure compares the annualized treated bleed rate during prophylaxis with the rate recorded during the run-in period.
  • 4The FDA advised Hemab to consider a randomized controlled study, but the company proceeded with a single-arm trial.
  • 5Sutacimig has three FDA designations for Glanzmann thrombasthenia: Fast Track, Orphan Drug and Breakthrough Therapy.

Sources